BeiGene, a Beijing novel oncology drug company, reported early positive data from a Phase I trial of BGB-3111, a BTK inhibitor being tested in patients with advanced B cell malignancies. In preliminary results, BGB-3111 seemed well tolerated and showed single-agent activity in a range of B cell malignancy subtypes (an overall response rate of 93% in chronic lymphocytic leukemia, for example). The results were presented at the recent ASH annual meeting.
